Dr. Reddy’s Laboratories Limited (NYSE:RDY) is an Indian multinational pharmaceutical firm headquartered in Hyderabad, India. In this thesis, I’ll primarily be analyzing a number of drug launches by the corporate within the US market. I will even analyze the danger confronted by the corporate and its valuation at present value ranges. I assign a maintain ranking for RDY after bearing in mind all the expansion and danger elements.
Dr. Reddy’s Laboratories Limited is a multinational pharmaceutical firm having operations in additional than 65 nations. The firm operates via Pharmaceutical Services and Active Ingredients (PSAI), Proprietary Products, Global Generics, and different segments. Its PSAI section manufactures and sells energetic pharmaceutical substances and intermediates, that are used as uncooked supplies in different completed items. Along with this, the PSAI section can also be concerned in contract analysis providers, and it manufactures and markets energetic pharmaceutical substances and steroids as per particular buyer necessities. The international Generics section of the corporate produces and sells prescription and over-the-counter pharmaceutical completed merchandise which are marketed both beneath a model title or as ultimate generic dosages which are therapeutically equal to branded formulations. Additionally, this division operates within the biologics business. The firm’s Proprietary Products section focuses on the analysis and improvement of differentiated formulations. The Others section works on most cancers and inflammation-related drug improvement.
Multiple Product Launches
RDY is well-known for fixed improvements within the market. The firm has launched a number of medicine within the US market lately that are anticipated to drive vital progress within the close to future.
Bortezomib launch within the US: RDY, on 27 July 2022, announced the launch of its drug bortezomib within the US market after receiving approval from US Food and Drug Administration (USFDA). This drug is a generic equal of Takeda Pharmaceutical’s (TAK) Velcade injection. RDY has launched its drug bortezomib for injection of three.5mg per 10 mL single-dose vial presentation for subcutaneous (SQ) or intravenous (IV) use. This drug is on the core of treating myeloma, a malignant tumor of the bone marrow. To quantify the dimensions of this drug launch, allow us to take a look at Velcade drug gross sales within the US market. The Velcade drug by Takeda Pharmaceutical had recorded $1.2 billion in sales within the 12 months ending May 2022. RDY has an excellent alternative with this drug launch within the US market.
Generic medicine launch for allergic reactions within the US: RDY, on 22 July 2022, announced the launch of over-the-counter (OTC) Fexofenadine HCl 180 mg and Pseudoephedrine HCl 240 mg Extended-Release tablets after approval from US Food and Drug Administration (USFDA). These medicine are the store-brand equal of Allegra-D 24 H.R. within the US. These medicine primarily deal with nasal and sinus congestion brought on by colds or allergic reactions. The Allegra-D24 HR has $45 million in gross sales for the 12-month interval ending May 2022 within the US market as per IRI.
Marc Kikuchi, CEO, North America Generics, Dr. Reddy’s Laboratories, said:
The launch of Dr. Reddy’s Fexofenadine HCl 180 mg and Pseudoephedrine HCl 240 mg Extended Release Tablets, USP, is a crucial addition to our higher respiratory portfolio of OTC merchandise, This first-to-market launch is a testomony to our deep capabilities and our continued efforts to deliver top quality, inexpensive store-brand alternate options for our prospects and sufferers.
The firm has introduced numerous drug launches within the month of June and May as effectively. These drug launches present the corporate with an revolutionary product combine every so often. Also, they’re the first progress driving issue for the corporate by increasing in numerous drug segments in addition to increasing current product strains. I imagine the corporate will profit drastically from these product launches within the coming years, however it’s pretty valued at present value ranges, and it’s advisable to not take any contemporary place within the stock. I like to recommend to attend for a value correction within the stock earlier than initiating a shopping for place.
Key Risk Factor
Commodity Price Volatility: The firm’s procurement and gross sales of energetic drug substances, such because the uncooked materials parts for these energetic pharmaceutical substances, are the first supply of its publicity to market danger with regard to commodity costs. The availability of uncooked supplies has a big influence on the enterprise. These are commodity merchandise, and their prices can change significantly in a brief period of time. Although the prices of uncooked supplies utilized within the firm’s energetic pharmaceutical substances enterprise are sometimes extra variable, uncooked materials costs typically change consistent with commodity cycles. Most of the corporate’s working bills are associated to the price of uncooked supplies. That’s why a fast improve in commodity costs could have an antagonistic influence on the corporate’s operational earnings.
Recently the corporate has launched many medicine, majorly within the USA. I feel it is too early to estimate these launches’ results on the corporate’s financials. I’m conserving a conservative estimate, and I’ll replace my estimates as soon as I get certainty of the influence of the launches on the financials within the coming quarters. The launches are a giant progress catalyst in the long run, however I’ll await one or two quarters to get a transparent image of the monetary influence of the occasion.
The firm is at present buying and selling at $51.50 with a market capitalization of $8.56 billion. The firm’s present trailing PE a number of is 29.49x. I estimate the EPS of FY2022 to be $2.42, which supplies the main PE a number of of 21.62x. I imagine the corporate is pretty valued on the present value ranges, and the forecasted stable progress as a consequence of current launches is an efficient motive to carry the stock for the long run however it’s advisable to attend for a value correction earlier than taking any new place within the stock.
The firm’s quant ranking and issue grades of Seeking Alpha completely align with my funding thesis and basic valuation. According to Seeking Alpha’s quant ranking, the corporate has a maintain ranking. The firm has C- in valuation, which helps my maintain ranking, and It has B+ in progress, which aligns with future progress. The firm has A- in profitability, B in momentum, and C- in revisions. After contemplating all these elements, I imagine the corporate’s valuation isn’t engaging.
Recently, the corporate has launched numerous medicine, which has created substantial progress prospects, however in keeping with the PE valuation metric, the corporate is pretty valued. After contemplating the present stock value and the expansion elements of the corporate, I imagine its valuation isn’t engaging to make a brand new place. Hence, I assign a maintain ranking for RDY.